- Home
- MEGL vs APRE Comparison
MEGL vs APRE Comparison
Compare MEGL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | APRE |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.9M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MEGL | APRE |
|---|---|---|
| Price | $1.28 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 17.7K | ★ 71.0K |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,296,394.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.02 | $0.96 |
| 52 Week High | $5.52 | $5.00 |
Technical Indicators
Market Signals| Indicator | MEGL | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 32.28 |
| Support Level | $1.22 | $1.08 |
| Resistance Level | $1.34 | $1.29 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 50.00 | 21.26 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.